Xtent to liquidate
This article was originally published in The Gray Sheet
Executive Summary
Developer of the Custom NX biolimus A9-eluting stent with adjustable lengths and bioabsorbable polymer plans to liquidate its assets and dissolve the company, subject to shareholder approval, Xtent announces May 15. The firm cited "continued challenges" in the capital markets when it eliminated most of its employees and began looking for buyers in January (1"The Gray Sheet" Feb. 2, 2009, In Brief)